| everolimus / Generic mfg. |
NCT00655252 / 2007-005460-28: Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy |
|
|
| No Longer Available | N/A | | US, Canada, Europe, RoW | Everolimus | Novartis Pharmaceuticals | Metastatic Renal Cell Cancer | | | | |
|
|
|
ChiCTR-OON-16008330: Clinical study of PD-1 inhibitor with everolimus for relapsed and refractory brain tumors |
|
|
| Recruiting | N/A | 40 | | Everolimus 10mg PO QD ;PD-1 inhibitor 2mg/kg ivgtt Q3W ;Everolimus 10mg PO QD+PD-1 inhibitor 2mg/kg ivgtt Q3W ;Everolimus 10mg PO QD+PD-1 inhibitor 2mg/kg ivgtt Q3W | Renji Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, PD-1 inhibitor is supplied by MSD | Malignant Glioma | | | | |
| No Longer Available | N/A | | Europe, Canada, US, RoW | everolimus (RAD) | Novartis Pharmaceuticals | Organ Transplantation | | | | |
ChiCTR2100048697: Molecular phenotype study of advanced refractory solid tumors and exploratory clinical trials of PDX model construction |
|
|
| Completed | N/A | 124 | | ARP inhibitor based combination therapy ;Trametinib based combination therapy ;Everolimus based combination therapy ;Combination therapy | The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, No funds | Refractory solid tumor | | | | |
NCT04212702: ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments |
|
|
| Active, not recruiting | N/A | 123 | RoW | Hormonal therapy-based treatments, HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only | National Taiwan University Hospital, Novartis | Metastatic Breast Cancer | 02/20 | 12/21 | | |
NCT03413722: Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus |
|
|
| Recruiting | N/A | 30 | US | Tacrolimus, Prograf, Everolimus | University of Kansas Medical Center, Novartis Pharmaceuticals | End Stage Renal Disease | 09/21 | 12/21 | | |
NCT05108740: MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer |
|
|
| No Longer Available | N/A | | NA | everolimus, Afinitor | Novartis Pharmaceuticals | Advanced Hormone Receptor Positive (HR+) Breast Cancer | | | | |
ChiCTR1900021070: A randomized controlled trial for Neoadjuvant Everolimus Plus EC followed by T Compared With EC followed by T in patients with ER-positive, HER2-negative operable breast cancer |
|
|
| Recruiting | N/A | 214 | | Everolimus (10 mg/ day, Po) combined with EC (famacin 90mg/m2 iv d1+ cyclophosphamide 600mg/m2 iv d1, 21 days in a cycle) 4 cycles followed by T (docetaxel 100mg/m2, iv, d1, 21 days in a cycle) 4 cycles ; EC (famacin 90mg/m2 iv d1+ cyclophosphamide 600mg/m2 iv d1, 21 days in a cycle) 4 cycles followed by T (docetaxel 100mg/m2, iv, d1, 21 days in a cycle) 4 cycles | SUN YAT-SEN MEMORIAL HOSPITAL, SYSU; SUN YAT-SEN MEMORIAL HOSPITAL, SYSU, SUN YAT-SEN MEMORIAL HOSPITAL, SYSU | Breast Cancer | | | | |
NCT06338306: Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes |
|
|
| Recruiting | N/A | 25 | Europe | Tacrolimus（FK506） | Fondazione IRCCS Policlinico San Matteo di Pavia | Heart Transplant Failure | 06/22 | 06/25 | | |
| Recruiting | N/A | 112 | Europe | additional blood sample | Centre Hospitalier Universitaire de Besancon | Breast Cancer | 05/22 | 05/22 | | |
NCT03493165: Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) |
|
|
| Available | N/A | | NA | Everolimus, Zortress, Afinitor, and Afinitor Disperz | The University of Texas Health Science Center at San Antonio | Uterine Sarcoma | | | | |
Treat ER+ight, NCT02753686: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy |
|
|
| Completed | N/A | 440 | Canada | Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy | Novartis Pharmaceuticals | HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer | 12/22 | 12/22 | | |
NCT05734157: CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery |
|
|
| Active, not recruiting | N/A | 76 | Europe | Peripheral PTA with a drug coated balloon | Chansu Vascular Technologies | Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion | 02/23 | 09/25 | | |
NCT03493152: Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) |
|
|
| Temporarily Not Available | N/A | | NA | Everolimus, Zortress, Afinitor, and Afinitor Disperz | The University of Texas Health Science Center at San Antonio | Gastrointestinal Stromal Tumor | | | | |
| Recruiting | N/A | 600 | US | Sirolimus, Rapamune, rapamycin, Everolimus, Afinitor | University of Cincinnati, Rare Diseases Clinical Research Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), The LAM Foundation | Lymphangioleiomyomatosis | 07/24 | 07/25 | | |
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
NCT06317298: Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy |
|
|
| Recruiting | N/A | 36 | RoW | Fruquintinib and Everolimus | Peking University First Hospital | Renal Cell Carcinoma, Clear Cell, Somatic | 08/25 | 12/25 | | |
| Not yet recruiting | N/A | 260 | Europe | | University Hospital, Brest | Transplant; Complication, Failure | 08/25 | 08/25 | | |
| Active, not recruiting | N/A | 682 | Europe | Blood sampling, Tumor sampling, Stool sampling | Institut Curie | Cancer | 09/24 | 09/25 | | |
STARR, NCT03955172: Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection |
|
|
| Recruiting | N/A | 20 | Europe | Everolimus | Hospices Civils de Lyon | Kidney Transplant Failure and Rejection | 12/27 | 12/27 | | |
NCT04414735: Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients |
|
|
| Recruiting | N/A | 30 | Europe | Extracorporeal Photopheresis | Fundacion Clinic per a la Recerca Biomédica, Mallinckrodt | Kidney Transplant Rejection | 03/25 | 12/25 | | |
NCT05268952: A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0) |
|
|
| Recruiting | N/A | 100 | Europe, RoW | Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT) | University Hospital, Antwerp, Universiteit Antwerpen | Neuroendocrine Tumors | 05/25 | 12/25 | | |
ELF, NCT04542733: The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient |
|
|
| Recruiting | N/A | 50 | RoW | Everolimus, reduced dose tacrolimus | King Chulalongkorn Memorial Hospital | Kidney Transplant Infection, BK Virus Infection | 09/25 | 09/25 | | |
NCT04324502: Mobile Application to Collect PRO Data in NET Patients |
|
|
| Recruiting | N/A | 2000 | Europe | | King's College Hospital NHS Trust, Ampersand Health Ltd, Neuroendocrine Cancer UK | Neuroendocrine Neoplasms (Tumours) | 07/26 | 07/26 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
